Qube Research & Technologies Ltd
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1729829
LONDON, X0
Position in ALNY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$240,437,176
-$36,893,756 QoQ
Shares Held
798,715
-4.7% QoQ
Ownership
0.597%
of shares outstanding
% of Portfolio
0.27%
of 13F equity value
Holder Rank
#31
of 784 holders
Holding Since
Jun 2020
15 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Derivatives in ALNY
reported options exposure · as of Mar 31, 2025CallValue
$27,002
CallShares
100
PutValue
$27,002
PutShares
100
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Qube Research & Technologies Ltd holds $2,443,042,063 across 169 Biotechnology names. ALNY ranks #1 (9.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
798,715 | $240,437,176 | |
| 2 | INSM |
INSMED Inc
|
1,682,334 | $179,370,451 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
221,607 | $138,180,828 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,454,496 | $122,254,613 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
426,336 | $104,354,262 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
659,678 | $87,559,060 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
1,443,230 | $81,989,896 | |
| 8 | RPRX |
Royalty Pharma plc
|
1,412,112 | $79,177,119 |
All Filings in ALNY
Export CSV
19 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $240,437,176 | 798,715 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $277,330,932 | 838,187 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $308,049,911 | 774,676 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $369,942,768 | 811,278 | Shares | Sole | 2025-11-14 | |
| 2025-03-31 | $27,002 | 100 | Put | Sole | 2025-05-15 | |
| 2025-03-31 | $89,200,296 | 330,347 | Shares | Sole | 2025-05-15 | |
| 2025-03-31 | $27,002 | 100 | Call | Sole | 2025-05-15 | |
| 2024-12-31 | $23,531 | 100 | Put | Sole | 2025-02-14 | |
| 2024-12-31 | $114,186,530 | 485,260 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $41,849,114 | 152,162 | Shares | Sole | 2024-11-14 | |
| 2024-09-30 | $55,006 | 200 | Call | Sole | 2024-11-14 | |
| 2024-03-31 | $16,552,931 | 110,759 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $3,531,896 | 18,452 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $177,100 | 1,000 | Shares | Sole | 2023-11-13 | |
| 2022-09-30 | $290,832 | 1,453 | Shares | Sole | 2022-11-14 | |
| 2022-03-31 | $1,135,028 | 6,951 | Shares | Sole | 2022-05-09 | |
| 2021-12-31 | $598,108 | 3,527 | Shares | Sole | 2022-02-10 | |
| 2021-09-30 | $8,477,380 | 44,899 | Shares | Sole | 2021-11-12 | |
| 2020-06-30 | $6,732,932 | 45,459 | Shares | Sole | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||